Gastroesophageal adenocarcinoma

This early-stage trial tests a personalized cancer vaccine for people with bladder or stomach cancer who still have tiny amounts of cancer DNA in their blood after surgery. The vaccine is made from unique proteins in each person's tumor and aims to train the immune system to find…

This clinical trial is looking at the best timing for local treatments like surgery or radiation in people with esophageal or stomach cancer that has spread to only a few spots. All participants first get 4 months of standard drug therapy. Then, depending on their response, they …

This phase 2 trial tests whether a series of procedures to remove cancerous tumors, given one after another, can improve outcomes for people with stage IV foregut cancers (like stomach, pancreas, or bile duct cancer) who have no detectable cancer DNA in their blood after initial …

This study compares two drug combinations for people with advanced stomach, gastroesophageal junction, or esophageal cancer that hasn't been treated yet. One group gets pumitamig plus chemotherapy, the other gets nivolumab plus chemotherapy. The goal is to see which combo works b…

This study tests two new drug combinations for people with advanced stomach, gastroesophageal junction, or esophageal cancer that has worsened after initial treatment. About 210 participants will receive either an experimental antibody-drug conjugate plus chemotherapy, or a stand…

This study tests whether a stronger chemotherapy mix (mFOLFIRINOX) works better than the standard mix (FOLFOX) for people with advanced stomach, esophageal, or gastroesophageal junction cancer that cannot be removed by surgery. Some participants also receive the immunotherapy dru…

This study tests new experimental drugs combined with standard chemotherapy and immunotherapy for people with advanced stomach, gastroesophageal junction, or esophageal cancer that cannot be removed by surgery or has spread. About 160 participants will receive the combination to …

This phase II trial tests whether adding paclitaxel directly into the abdomen, alongside standard systemic chemotherapy, is feasible for people with gastrointestinal cancers that have spread to the peritoneal lining. The study includes patients with gastric, colorectal, appendice…

This study tests a new drug called ivonescimab combined with standard chemotherapy (FOLFOX) in people with advanced HER2-negative stomach or esophagus cancer that has not been treated before. The goal is to see if the combination can keep the cancer from growing for at least 6 mo…

This early-stage trial is testing a new treatment called DISP-10 for people with advanced gastrointestinal cancers, including colorectal and stomach cancers. The treatment combines a virus (DV-10) with specially engineered immune cells (CAR T cells) to attack cancer. The study ai…

This study tests a new drug called ASP546C in people with advanced stomach, gastroesophageal junction, pancreatic, or certain other solid tumors. The drug is given as an infusion every 3 weeks. The study has two parts: Part 1 finds the best dose in stomach/GEJ cancer patients, an…

This study is testing a drug called tislelizumab combined with chemotherapy as a first treatment for people with advanced stomach or esophageal cancer that cannot be removed by surgery or has spread. It focuses on racial and ethnic minority groups in the US, including Black, Hisp…

This early-stage study tests a new drug called HH160 in about 56 adults with advanced solid tumors (cancers that have spread). The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. Participants will receive HH160 alone or with other cancer tr…

This study tests several new drug combinations given before and after surgery for stomach or esophageal cancer. About 100 people with resectable tumors will receive these treatments to see if they are safe and can shrink or eliminate the cancer. The goal is to improve outcomes by…

This study tests whether adding a drug called zanidatamab to the usual chemotherapy can slow or stop the growth of advanced stomach, esophagus, or gastroesophageal junction cancer that is HER2-positive. About 168 adults who have already tried one standard treatment will be random…

This study tests a personalized treatment for stomach or esophageal cancer. Doctors will use tumor markers to pick the best mix of chemotherapy, immunotherapy, and targeted drugs. The goal is to shrink the cancer so much that some patients may avoid surgery entirely. About 121 ad…

This treatment program tests a personalized cell therapy for people with advanced pancreatic or colorectal cancers that have a specific genetic mutation (KRAS G12D). Patients' own immune cells are collected, genetically engineered to recognize and attack the cancer, and then infu…

This study tests a new drug called Spevatamig (PT886) in people with advanced stomach, pancreatic, or bile duct cancers that have spread or cannot be removed by surgery. The drug is a type of antibody that targets two proteins on cancer cells to help the immune system attack them…

This study tests a new drug, BHB810, in adults with advanced stomach or gastroesophageal junction cancer that has not responded to standard treatments. The drug is given as an IV infusion every two weeks. The main goals are to check safety and find the best dose, while also seein…

This phase 2 study is testing whether adding two newer drugs—pembrolizumab (an immunotherapy) and trastuzumab (a targeted therapy)—to standard chemotherapy can help people with HER2-positive esophageal or stomach cancer that can be surgically removed. About 49 adults will receive…

This Phase II trial is testing a combination of three drugs—zanidatamab, pembrolizumab, and chemotherapy—in 80 people with advanced stomach or esophageal cancer that has spread and tests positive for HER2 and PD-L1. The goal is to see if this triple therapy can keep the cancer fr…

This Phase 2 trial is testing several new drug combinations in people with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread. The study aims to see if these combinations can shrink tumors and keep them from growing for at least 6…

This study tests whether adding a targeted drug (LM-302) to standard immunotherapy and chemotherapy before surgery can improve outcomes for people with a specific type of stomach cancer that has a protein called claudin 18.2. About 88 adults with advanced but removable stomach ca…

This study tests a combination of drugs (LM-302, S-1, and intraperitoneal paclitaxel) with or without another drug (cadonilimab) in people with a specific type of advanced stomach cancer (Claudin 18.2-positive) that has spread to the lining of the abdomen. The goal is to see if t…

This early-phase trial is testing whether adjusting chemotherapy based on how a patient's tumor responds can improve outcomes for people with stomach or gastroesophageal junction cancer. About 20 participants with stage IB to III disease will receive standard chemo combinations (…

This phase 3 trial is testing whether a new combination of drugs (SHR-A1811, adebrelimab, and chemotherapy) works better than the current standard treatment for people with advanced stomach or gastroesophageal junction cancer that has not been treated before. The study will enrol…

This Phase 3 trial tests whether adding fruquintinib to the standard drug trifluridine/tipiracil helps people with advanced stomach or gastro-esophageal cancer live longer. About 324 participants who have already tried at least two prior treatments will receive either the combo o…

This early-phase trial is testing a new drug called BDC-4182 in people with advanced gastric or gastroesophageal cancer that has spread or cannot be removed. The drug is designed to attach to a protein on cancer cells and stimulate the immune system to attack them. The study will…

This phase II trial is testing a rotating schedule of two chemotherapy regimens (FOLFOX and FOLFIRI), with or without the immunotherapy nivolumab, in 38 people with advanced HER2-negative gastric or esophageal cancer. The goal is to see if this approach improves tumor shrinkage a…

This study tests whether adding the targeted drug zolbetuximab to standard chemotherapy (paclitaxel and ramucirumab) can help people with advanced stomach or gastroesophageal cancer live longer. It includes 100 adults whose tumors have a specific protein called CLDN18.2. Particip…

This early-phase trial tests a new combination of the immunotherapy drug tislelizumab plus standard chemotherapy (FLOT) given before surgery for people with stomach, esophageal, or gastroesophageal junction cancer that can be removed. The goal is to see if this longer pre-surgery…

This early-stage study tests whether combining two drugs (sacituzumab govitecan and capecitabine) is safe for people with advanced gastrointestinal cancers that have stopped responding to standard treatments. About 20 adults with stomach, colorectal, or pancreatic cancer will tak…

This study tests a different chemotherapy drug (trifluridine/tipiracil) for people with metastatic colorectal or gastroesophageal cancer who have a genetic condition (DPD deficiency) that makes standard chemo very toxic. About 73 participants will receive this drug along with oth…

This study tests a new chemotherapy drug called utidelone, given as a capsule, together with standard chemotherapy for people with advanced stomach or gastroesophageal junction cancer that has not been treated before. The trial will enroll about 778 participants across multiple c…

This Phase 2 trial is testing an experimental drug called HLX43 in 60 people with advanced gastric or gastroesophageal junction cancer. HLX43 is a targeted therapy that delivers a potent chemotherapy agent directly to cancer cells. The study aims to find the best dose and see how…

This early-stage trial is testing a powerful mix of five chemotherapy drugs for people with advanced upper gastrointestinal cancers, including pancreatic and stomach cancers. The study uses each person's genetic profile to adjust the dose of one of the drugs (irinotecan) to try t…

This trial tests an experimental imaging agent called [68Ga]Ga-DWJ155 in adults with advanced cancers of the breast, lung, or stomach. The agent is designed to attach to tumor cells and show up on PET scans, helping doctors see where cancer has spread. Researchers will measure ho…

This study is testing whether a special type of PET/MRI scan, using a tracer called FAZA, can measure low oxygen levels (hypoxia) in tumors of patients with metastasized gastro-oesophageal cancer. The goal is to see if this scan can predict how well patients will respond to stand…

This study tests whether a dye called pafolacianine (CYTALUX™) can make cancer cells glow under near-infrared light during surgery. Fifteen adults with gastric, esophageal, or appendiceal cancer will receive the dye before standard surgery. Surgeons will use a special camera to l…

This study looks at whether a program of exercise and dietary changes can improve or maintain quality of life for people with incurable stomach or esophageal cancer. Researchers will compare two groups of about 196 patients: one group receives standard care, and the other adds a …

This study looks at whether people with certain cancers prefer getting their immune therapy as a shot under the skin (subcutaneous) or through a needle in a vein (intravenous). About 880 adults who are already eligible for standard treatments like nivolumab or pembrolizumab will …